Eton Pharmaceuticals (NASDAQ:ETON) CFO Sells $42,148.62 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) CFO James Gruber sold 2,631 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $16.02, for a total transaction of $42,148.62. Following the completion of the transaction, the chief financial officer owned 204,753 shares of the company’s stock, valued at approximately $3,280,143.06. The trade was a 1.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON opened at $17.30 on Friday. Eton Pharmaceuticals, Inc. has a twelve month low of $4.23 and a twelve month high of $21.48. The firm has a market cap of $463.99 million, a P/E ratio of -108.13 and a beta of 1.13. The company has a 50 day moving average of $15.00 and a 200 day moving average of $15.46. The company has a quick ratio of 1.16, a current ratio of 1.77 and a debt-to-equity ratio of 1.14.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.09). Eton Pharmaceuticals had a negative return on equity of 0.73% and a negative net margin of 7.10%.The firm had revenue of $18.93 million during the quarter, compared to analysts’ expectations of $16.71 million. As a group, research analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ETON shares. Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, May 14th. Wall Street Zen lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. HC Wainwright reiterated a “buy” rating and set a $35.00 target price (up from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. Finally, B. Riley reiterated a “buy” rating and set a $26.00 target price (up from $24.00) on shares of Eton Pharmaceuticals in a research note on Friday, May 16th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Eton Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $29.67.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ETON. Ameritas Investment Partners Inc. bought a new position in Eton Pharmaceuticals in the 2nd quarter worth $37,000. Legal & General Group Plc bought a new position in Eton Pharmaceuticals in the 2nd quarter worth $41,000. AlphaQuest LLC bought a new position in Eton Pharmaceuticals in the 1st quarter worth $53,000. Tower Research Capital LLC TRC bought a new position in Eton Pharmaceuticals in the 4th quarter worth $86,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Eton Pharmaceuticals in the 2nd quarter worth $87,000. Institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.